NeoGenomics appoints Lynn Tetrault as Interim CEO; Chief Strategy Officer departing May 27

NEOGENOMICS INC

Lynn Tetrault named Chair of the Board and Interim CEO, effective May 12, 2022; no compensation change.
Company disbands Interim Office of the CEO; Tetrault previously served as Executive Chair since March.
Board's external search for permanent CEO is 'on track' per Lead Independent Director Michael Kelly.
Chief Strategy and Corporate Development Officer Douglas Brown leaves May 27 to pursue other interests.
CFO William Bonello and Chief Culture Officer Jennifer Balliet remain in their roles.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.